MedPath

Chiesi USA, Inc.

Chiesi USA, Inc. logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:2
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

15

FDA:15

Drug Approvals

FERRIPROX

Approval Date
Mar 31, 2025
FDA

ELFABRIO

Approval Date
Feb 7, 2024
FDA

Juxtapid

Approval Date
Jan 25, 2024
FDA

Mycapssa

Approval Date
Jan 10, 2024
FDA

Bronchitol

Approval Date
Jan 1, 2024
FDA

BETHKIS

Approval Date
Feb 24, 2023
FDA

Lamzede

Approval Date
Feb 21, 2023
FDA

KENGREAL

Approval Date
Sep 6, 2022
FDA

Cleviprex

Approval Date
Sep 6, 2022
FDA

Revcovi

Approval Date
Aug 31, 2022
FDA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

Active, not recruiting
Conditions
Myocardial Infarction
First Posted Date
2019-09-03
Last Posted Date
2025-06-13
Lead Sponsor
Chiesi USA, Inc.
Target Recruit Count
5050
Registration Number
NCT04076813
Locations
🇺🇸

The Regents of the University of California on behalf of its San Diego campus, La Jolla, California, United States

🇺🇸

Christiana Care Health Services, Inc., Newark, Delaware, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

and more 8 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.